Moleculin Biotech, Inc.
MBRX
$0.9502
$0.07538.61%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 8.79M | 8.88M | 9.34M | 9.77M | 10.02M |
Depreciation & Amortization | 125.00K | 129.00K | 130.00K | 130.00K | 128.00K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 26.64M | 28.92M | 27.73M | 27.95M | 29.63M |
Operating Income | -26.64M | -28.92M | -27.73M | -27.95M | -29.63M |
Income Before Tax | -21.76M | -30.15M | -25.17M | -26.82M | -29.77M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -21.76 | -30.15 | -25.17 | -26.82 | -29.77 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -21.76M | -30.15M | -25.17M | -26.82M | -29.77M |
EBIT | -26.64M | -28.92M | -27.73M | -27.95M | -29.63M |
EBITDA | -26.51M | -28.79M | -27.60M | -27.83M | -29.50M |
EPS Basic | -6.94 | -11.65 | -11.62 | -12.94 | -15.06 |
Normalized Basic EPS | -4.34 | -7.28 | -7.26 | -8.09 | -9.41 |
EPS Diluted | -6.94 | -11.65 | -11.62 | -12.94 | -15.06 |
Normalized Diluted EPS | -4.34 | -7.28 | -7.26 | -8.09 | -9.41 |
Average Basic Shares Outstanding | 13.76M | 10.74M | 9.02M | 8.45M | 7.90M |
Average Diluted Shares Outstanding | 13.76M | 10.74M | 9.02M | 8.45M | 7.90M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |